Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

DISEASE CHARACTERISTICS:

Histologically confirmed melanoma

Metastatic disease

Measurable or evaluable non-CNS disease

Measurable disease, defined as a unidimensionally measurable lesion as determined by physical exam, x-ray, CT scan, MRI, or other radiographic procedure

Evaluable disease, defined as a lesion that can be seen radiographically but is not unidimensionally measurable

Previously irradiated lesions with documented progression are allowed provided there are no other sites of metastatic disease

No active brain metastases

Previously treated, responding brain metastases allowed, provided there is measurable disease outside of the CNS

At least 3 weeks since prior chemotherapy and 6 weeks since prior radiotherapy for CNS disease

PATIENT CHARACTERISTICS:

Inclusion criteria:

ECOG performance status 0-2
Life expectancy ≥ 3 months
ANC ≥ 1,200/mm^3
Platelet count ≥ 100,000/mm^3
Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min
Bilirubin ≤ 3.0 mg/dL
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
EKG with no evidence of serious arrhythmia or recent myocardial infarction

Exclusion criteria:

Active infection
Chronic underlying immunodeficiency disease
Other serious concurrent illness
Other forms of cancer within 5 years of initial diagnosis except nonmelanoma skin cancer and cervical cancer
Congestive heart failure or myocardial infarction within the past 6 months

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

See Disease Characteristics
At least 6 weeks since prior radiotherapy
More than 4 weeks since prior surgery
Prior biologic therapy allowed

Exclusion criteria:

Prior cytotoxic agents
Prior sorafenib tosylate, bevacizumab, or oxaliplatin
Concurrent biological therapy, except growth factors for anemia, neutropenia, or thrombocytopenia
Concurrent radiotherapy, chemotherapy, or surgery